Testosterone Replacement Therapy and the Risk of Hypoglycemia

We report the case of a 45-year-old man with a history of Klinefelter syndrome undergoing testosterone replacement therapy, and with type 2 diabetes treated with metformin with poor metabolic control. When vildagliptin was added to his treatment, he presented hypoglycemia after the testosterone inje...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Analía Verónica, Costanzo, Pablo René, Peuchot, Verónica Andrea, Knoblovits, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885825/
https://www.ncbi.nlm.nih.gov/pubmed/31827946
http://dx.doi.org/10.1155/2019/9616125
_version_ 1783474798190395392
author Yamaguchi, Analía Verónica
Costanzo, Pablo René
Peuchot, Verónica Andrea
Knoblovits, Pablo
author_facet Yamaguchi, Analía Verónica
Costanzo, Pablo René
Peuchot, Verónica Andrea
Knoblovits, Pablo
author_sort Yamaguchi, Analía Verónica
collection PubMed
description We report the case of a 45-year-old man with a history of Klinefelter syndrome undergoing testosterone replacement therapy, and with type 2 diabetes treated with metformin with poor metabolic control. When vildagliptin was added to his treatment, he presented hypoglycemia after the testosterone injection. We highlight this not widely reported drug interaction between hypoglycemic agents and testosterone.
format Online
Article
Text
id pubmed-6885825
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-68858252019-12-11 Testosterone Replacement Therapy and the Risk of Hypoglycemia Yamaguchi, Analía Verónica Costanzo, Pablo René Peuchot, Verónica Andrea Knoblovits, Pablo Case Rep Endocrinol Case Report We report the case of a 45-year-old man with a history of Klinefelter syndrome undergoing testosterone replacement therapy, and with type 2 diabetes treated with metformin with poor metabolic control. When vildagliptin was added to his treatment, he presented hypoglycemia after the testosterone injection. We highlight this not widely reported drug interaction between hypoglycemic agents and testosterone. Hindawi 2019-11-17 /pmc/articles/PMC6885825/ /pubmed/31827946 http://dx.doi.org/10.1155/2019/9616125 Text en Copyright © 2019 Analía Verónica Yamaguchi et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Yamaguchi, Analía Verónica
Costanzo, Pablo René
Peuchot, Verónica Andrea
Knoblovits, Pablo
Testosterone Replacement Therapy and the Risk of Hypoglycemia
title Testosterone Replacement Therapy and the Risk of Hypoglycemia
title_full Testosterone Replacement Therapy and the Risk of Hypoglycemia
title_fullStr Testosterone Replacement Therapy and the Risk of Hypoglycemia
title_full_unstemmed Testosterone Replacement Therapy and the Risk of Hypoglycemia
title_short Testosterone Replacement Therapy and the Risk of Hypoglycemia
title_sort testosterone replacement therapy and the risk of hypoglycemia
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885825/
https://www.ncbi.nlm.nih.gov/pubmed/31827946
http://dx.doi.org/10.1155/2019/9616125
work_keys_str_mv AT yamaguchianaliaveronica testosteronereplacementtherapyandtheriskofhypoglycemia
AT costanzopablorene testosteronereplacementtherapyandtheriskofhypoglycemia
AT peuchotveronicaandrea testosteronereplacementtherapyandtheriskofhypoglycemia
AT knoblovitspablo testosteronereplacementtherapyandtheriskofhypoglycemia

Ejemplares similares